Global Security Software Market in Retail Industry 2008-2012

Security software helps organizations achieve higher scalability in terms of data management and data operations. It’s features such as easy & protected access to content and ease of sharing content help organizations scale up their revenue. At present, organizations all over the world are undergoing a consolidation phase. This has led to the creation of huge data centers, which are managing complex information for enterprises. This data is termed as ‘knowledge’, and its security is of paramount issue for enterprises. According to a study, year 2008 witnessed a significant increase in security attacks by cybercriminals, whereas breaches through malwares and Trojans have increased by multi folds. Also, it has been found that a majority of the security breaches in 2008 was through internal resources.

Security issues are more prevalent in the retail industry wherein databases grow on a daily basis. Thus, security software that are protecting accessibility, integrity, and data transfer in organizations, are becoming a popular choice for such enterprises. Their easy to operate features, requirement specific solutions, and reliability have turned them as essential requirement for enterprises.

The report by TechNavio Insights forecasts the size of the Global Security Software Market in Retail Industry over the period 2008-2012. It segments the market into various geographic regions (representing the market size for each of these regions). Further, it discusses the key market trends, drivers and challenges of the Global Security Software Market in the Retail Industry, and profiles some of the key vendors of this Industry.

TechNavio Insights is a set of reports based on TechNavio – a market intelligence platform for the IT industry. It builds on the intelligence available within TechNavio, and leverages on the custom research experience of the ‘Technology Navigators’. TechNavio is built on years of experience of Infiniti Research in deep dive custom research and consulting for over 30 Fortune 500 companies and numerous large and mid-sized companies.

http://www.aarkstore.com/reports/Global-Security-Software-Market-in-Retail-Industry-2008-2012-19489.html

Active Optical Cables Market Report 2009 – Aarkstore Enterprise

Active Optical Cables Market Report 2009″ examines several focus segments generating significant business growth over the next five years. Fifteen separate market segment forecasts, covering four platform types, four bus standards, and five platform categories over a five-year forward time-interval, were analyzed as part of the overall Active Optical Cable (AOC) Market Analysis 2009.

Overall cumulative cable revenue is expected to exceed $8.5 billion (US) from 2009 through 2013 just for the application segments included in this report. Single-year revenue is expected to grow from the present-year level of <$100 million to over $1.1 billion in 2010, then up to over $2.6 billion by 2013. As additional application segments are included in the overall Market Analysis, the total revenue numbers should be expected to increase substantially over these conservative figures.

Total AOC cable count identified in this report should exceed 2 million units in 2009, and grow to over 75 million units by 2013. As in the revenue analysis above, we expect these AOC figures to expand as more application segments are studied, and as better attach rate forecasts become available. Growth in the overall AOC forecast should generate better supplier cost efficiency at both the AOC OEM cable providers as well as with their underlying material supplier communities.

Certain market forces influence changes in AOC attach rates used in this analysis. Several AOC users reported shifting away from copper cables towards AOC alternatives, even when the copper cables were technically cheaper for their shorter cable length application usage. One notable case was IBM’s Roadrunner supercomputer, which reportedly switched entirely to AOC, reporting 55 miles of cables in their first installation. Initial expectations were to use AOC models only for cables 5-10 meters or longer. As more and more customers experience this “Waterfall Effect,” significant increases in the overall AOC attach rate should occur, potentially 2-3x over the volumes included in this report.

Annual fiber shipments for active optical cables is expected to grow from ~13 million meters in 2009 to almost 434 million meters by 2013. Five-year cumulative shipments should total 1040 million meters. Certain OEMs use different designs for cables under 20 meters versus those in the 20-100 meter range. OEMs that target common optoelectronics designs capable of supporting broader cable length ranges will benefit from lower overall product costs as well as increased market response flexibility to changes in customer cable length preferences over time.

The average cable length covered by this study ranges from 1 to 100 meters. Volume is limited at the low end (<5 meters) by cost-efficient copper cable equivalents. At the 100-meter and longer range, more-effective passive optical designs take precedence with the customer base. In some application segments (such as mainframes), we expect to see an appreciable volume growth in the <5-meter cable length range, especially as supercomputers move towards quad-data-rate (40Gbps) fabrics. We anticipate a similar optical cable preference improvement in consumer applications as their preferred bus speeds begin to advance beyond 10Gbps .

As expected, the bulk of the AOC business is centered on models in the 10-20-Gigabits-per-second (Gbps) range. For cables carrying digital data below 5Gbps, including those <5 meters in length, copper can still provide suitable cost-effective technical solutions. For cables carrying data greater than 40Gbps, AOC usage can be expected to dominate copper cable share. While the number of 40Gbps ports today is relatively small compared to other speed groups, there is substantially growth in this segment, with its higher average attach rates making it a very attractive segment for AOC providers and their core materials providers.

AOC cable OEMs, as well as their underlying material suppliers (i.e., fiber-optic cable, VCSELs, optical detector/PIN diodes, and connectors), should benefit substantially from this growth, especially those with earlier market entry points.
 

Report Features :

Several key high-volume applications segments were chosen for this report. Emphasis was given to ones with products using digital electronics interfaces running either at or above 5Gbps, as well as those demanding extended cable lengths beyond 2-5 meters at these speeds. It is already well understood that copper-based cables are experiencing significant challenges in this performance range, thus offering significant copper displacement sales opportunity for AOC providers.

 For more information, please visit :
http://www.aarkstore.com/reports/Active-Optical-Cables-Market-Report-2009-13632.html

Research Report on the Low-Priced Laptop Market of China, 2008

The report thoroughly analyzes the supply and demand status, target consumers, competition strategy and development trends of Chinas low-cost notebook market. The report provides a high reference value for investors to understand Chinas low-cost notebook computer market situation, identify market entry points and grasp the investment opportunity.

Executive Summary

Low-priced laptop is a relative concept, whose specific price changes as time moves on. From 2007 to 2008, the price of low-priced laptops in China is about 4000 RMB or even below 3000 RMB. In short, on prices, the low-priced laptops stay in the lowest end of the notebook market prices. Some low-priced notebook computers, e.g. the HASEE low-cost computers, aim at low-end customers, e.g. students and small businesses. However on the whole market, low-priced notebook computers is not all for low-end customers. Take ASUS Eee PC as an example, it is popular with the crowd who need a “second” notebooks, and it positions for personal entertainment, portability instead of its hardware configuration.

Chinas low-cost notebook market will maintain rapid development in the next few years and even will seize part of the same areas of the PC such as desktop PC, UMPC and PMP, and other consumer electronics markets. Investment on Chinas low-cost PC market with bright prospects shows both opportunities and traps but there are also many errors and investment.

To know more about this report kindly visit:

http://www.aarkstore.com/reports/Research-Report-on-the-Low-Priced-Laptop-Market-of-China-2008-800.html

or email us at :
contact@aarkstore.com

Website : http://www.aarkstore.com

Key Trends in Offshoring Pharmaceutical R&D: Company strategies, emerging markets and impact on ROI – Aarkstore Enterprise

Key Trends in Offshoring Pharmaceutical R&D: Company strategies, emerging markets and impact on ROIs

Offshoring and outsourcing have become an increasingly critical contributor to pharma and biotech R&D strategies in recent years. They enable companies to focus on core competencies such as drug discovery or technology development whilst contracting out non-core processes to experts, often at lower costs. As offshore investments begin to mature and provide returns on investment, the opportunity to migrate individual components or whole segments of R&D portfolios will continue to rise.

‘Key Trends in Offshoring Pharmaceutical R&D’ is a report published evaluates the offshore R&D strategies that can reduce development times and improve productivity, with analysis of a variety of strategic partnerships, academic collaborations, and outsourcing opportunities. This report identifies emerging areas of technological and scientific significance across the globe and examines the offshore strategies and investments of the top 20 pharma and biotech companies across Asia, Australia, Central and Eastern Europe, Latin America and the Far East. This report also provides a financial and managerial valuation of leading companies based on their P/E ratio, return on assets (ROA) and return on investment (ROI) and measures company performance against the healthcare industry, pharmaceutical and biotechnology sectors and leading shares of the S&P500.

Key Findings

• Companies that have allocated over 60% of their R&D expenditure offshore have displayed greater shareholder return, operating margins, market capital growth and return on assets.

• The US currently attracts 53% of total industry R&D spend, however it is forecast that 20% of this expenditure will migrate to Asia Pacific by 2010. Australia, China and Singapore are emerging as key areas for scientific and technological investment.

• Leading pharma and biotech companies have undergone major R&D restructuring over the last five years and now adopt a focused, streamlined global approach which is increasingly reliant on offshore strategic partnerships, academic collaboration and outsourcing to establish networks of scientific expertise.

• Scientific and technological excellence within emerging economies is a key incentive for offshore investment, enabling companies to enhance innovation and productivity within their R&D programs.

• Managerial expertise is a critical factor driving the success of offshore investments, helping leading pharma and healthcare companies to outperform their peers and the S&P 500 index in 2008.

Use this report to…

• Assess the offshore R&D strategies of the top 20 pharma and biotech companies with this report’s analysis of offshore investment and deal trends over the last five years.

• Discover which geographic regions have the greatest potential for offshore R&D investment by identifying key areas of technological, scientific and academic expertise across Asia Pacific, Australia, Eastern Europe, Latin America, the Middle East and South Africa.

• Measure how the offshore strategies of the top 20 pharma and biotech companies have influenced their R&D productivity and efficiency with this report’s financial and managerial performance review, comparative analysis of healthcare/pharma/biotech sectors and S&P500 index assessment.

• Identify the key drivers and opportunities for offshore investment with this report’s analysis of major offshoring trends and R&D developments.

Explore issues including…

Shifting focus of R&D strategies. The industry has become more globalized in its R&D approach as part of efforts to improve productivity and efficiency. Networks of offshore partnerships and academic collaborations are now enabling companies to harness external expertise on a project by project basis.

Offshore investment in emerging economies. Companies are increasingly turning to emerging countries to counter the slowing growth of US and European markets. Investing in offshore R&D facilities provides companies with local expertise and a greater understanding of local economies.

Offshore opportunities in tertiary economies. The success of commercial opportunities in emerging markets has expanded the regional scope of investment, with Australia, Israel and Singapore all seen to provide labour arbitrage and access to specialists.

Focused managerial directives are critical. Successful R&D performance is underpinned by a streamlined R&D strategy which is well managed by a team of scientists, technologists and non-scientists which can guide global networks ensuring early go/no go decision making which builds on the core competencies of both internal and external researchers.

Discover…

• Which countries are attracting offshore investment?

• Which areas of research and technology are attracting offshore investment?

• How are the leading pharma and biotech companies changing their R&D programs?

• Which major companies and academic institutions have attracted offshore investment?

• What factors are driving offshore investment?

• What is the financial performance of the leading pharma and biotech companies based on P/E ratio compared to their peers and the S&P500?

• Which companies have delivered the best return on assets and return on investment during the last five years?

• How will offshore investment influence R&D productivity in the future?

 For more information, kindly visit :
http://www.aarkstore.com/reports/Key-Trends-in-Offshoring-Pharmaceutical-R-D-Company-strategies-emerging-markets-and-impact-on-ROI-13950.html

The Top Ten Global In-Vitro Diagnostics Companies: Positioning, performance and SWOT analyses – Aarkstore Enterprise

The Top 10 Global In-Vitro Diagnostics Companies: Positioning, performanceand SWOT analyses

The in-vitro diagnostics (IVD) market continues to grow at a steady pace, driven by new fields such as molecular diagnostics and a growing consumer awareness surrounding disease management. There is also an increasing focus on emerging markets, where healthcare infrastructures are improving. The industry is highly competitive and continues to witness large scale consolidation. Major in-vivo players are beginning to enter the in-vitro market and the regulatory environment is becoming even more stringent, increasing the time to approval for new products.

‘The Top 10 Global In-Vitro Diagnostics Companies’ is a report published explores the global competitive landscape of the IVD industry. This report analyses the size and structure of the market and identifies the latest developments in service offerings, new technologies, strategic approaches and competitive dynamics amongst leading companies. This report assesses the opportunities and threats facing the top 10 IVD companies in the future, and examines their current structure, financial performance, growth strategies and R&D activity. Growth forecasts for key products and regions are also provided.

Key Findings

The global in-vitro diagnostics (IVD) market is forecast to grow at a rate of 6% to reach $50.0bn in 2012. The market has been growing at a rate of 5-6% in recent years, reaching a value of $36.5bn in 2007.

Roche is the largest player in the market with a share of 20%. It is followed by Siemens and Abbott, who both hold 12% of the market. The IVD market is highly consolidated, with the top ten players holding close to 80% market share.

Molecular diagnostics, diabetes care, and emerging markets are the key growth drivers of the IVD industry. Theranostics is an emerging field with great promise and a number of players are making extensive efforts in the area.

Abbott’s IVD revenues increased by 10.8% to reach $4.4bn in 2007. However, Abbott’s diagnostics margins have been falling and it has recently announced a cost-cutting plan to improve the operating margin of its diagnostics unit. Abbott has also been faced with regulatory issues, with its diagnostics business coming under FDA supervision.

A number of large in-vivo players have entered the IVD market recently, signalling the convergence of the two diagnostic fields. Siemens Healthcare is a prominent example of this trend, following their acquisition of DPC, Bayer Diagnostics and Dade Behring.

Use this report to…

• Compare the performances of the top 10 IVD companies across key business segments and geographies with this report’s analysis of Roche Diagnostics, Siemens Healthcare, Abbott, J&J, Beckman Coulter, Becton Dickinson, bioMerieux, Bayer Diabetes, Sysmex and Bio-Rad.
• Understand the market dynamics shaping the global IVD industry, forecast key growth areas by product/region and identify deal-making patterns across clinical trials phases and key therapeutic areas.
• Evaluate the future prospects of major IVD players with this report’s examination of R&D expenditure, M&A activity, growth strategies and SWOT analyses for each of the top 10 companies.
• Measure the progress of other leading IVD companies by analysing the financial performances of Inverness, Chiron (Novartis), Olympus, Gen Probe, Hologic/Cytyc, Qiagen, Arkray, DiaSorin, Radiometer, Werfen.

Explore issues including…

Industry consolidation. The IVD market is consolidating further due to a large number of smaller companies striving to increase their market share through M&A activity. Big Pharma is also entering the IVD market through acquisitions.

Growth of molecular diagnostics. Molecular diagnostics is one of the fastest growing segments of the IVD market and is expected to grow at a CAGR of 14% over the next five years.

Stringent regulatory environment. Regulation within the IVD market is becoming increasingly stringent, particularly in the US where the FDA is intensifying its scrutiny on diagnostics companies.

Emergence of theranostics. Advances in the field of genomics are leading to the emergence of theranostics and personalized healthcare. Theranostics uses diagnostic testing to tailor disease treatment to individual needs through the application of molecular diagnostics. A number of players are currently conducting R&D and launching new products in the fields of theranostics and personalized healthcare.

Discover…

• What are the key trends and issues within the global IVD industry?
• Who are the top 10 companies in the IVD market?
• How do the leading companies compare in terms of financial performance, R&D capabilities and coverage by country and category?
• Who are the leading companies outside of the top 10?
• Which regions and segments offer the greatest growth opportunities for leading companies?
• What are the key strategies of the leading IVD companies and how do these strategies drive revenue and market share?
• What is the future outlook of the global IVD industry?

For more information, kindly visit :
http://www.aarkstore.com/reports/The-Top-Ten-Global-In-Vitro-Diagnostics-Companies-Positioning-performance-and-SWOT-analyses-13958.html

The Future of Software Delivery: The opportunities and challenges of emerging software delivery models – Aarkstore Enterprise

The Future of Software Delivery

The opportunities and challenges of emerging software delivery models

Report Overview

The way companies perceive and purchase their software is starting to change. Organizations no longer have to buy an on-premise application and host it on site, they can have it delivered on-demand, as a service or hosted by the software provider or a third party. But while these new models offer more choice in how they pay, receive and use applications, the proliferation of terms has led to some confusion amongst organizations about what they are and what they constitute. ‘The Future of Software Delivery: The opportunities and challenges of emerging software delivery models’ is a new report published by Business Insights that examines the market conditions that led to the emergence of these new models and the benefits they offer over traditional delivery types. This report also examines future market opportunities for software delivery models and how they may be extended to hardware platforms in the future.

Key Findings

The size of the on-demand CRM market will increase rapidly through 2009 to reach 27% of total market size as the CAGR for on-demand far exceeds that for the total CRM market.

There are signs that enterprises with revenue of more than $1bn are also adopting more SaaS (Software as a Service) applications. Originally some industry commentators predicted SaaS would not expand beyond SMBs into larger organizations.

A study by Triple Tree and the Software and Information Industry Association (SIIA) found that on-demand deployments were 50% to 90% faster, with a total cost of ownership five to ten times less than installed software.

The growth rates for on-demand CRM and ERP application markets are significantly higher than for the premise-based market. This is an indicator of the high levels of growth potential in the market.

Use this report to…

• Identify and target future growth areas of on-demand CRM using this report’s analysis of new market opportunities by sizeband, vertical and region, as well as market forecasts for key sectors.

• Understand the key issues in the software delivery market including vendor ecosystem, competitor offering and on-demand vs on-premise deployments.

• Enhance your sales and marketing strategies with this report’s comparison of different vendor strategies and recommendations on improving your go-to-market strategy. • Assess emerging software delivery models with this report’s cost analysis of implementing software via different models.

Explore issues including…

On-demand is often used interchangeably with SaaS, but it’s also a bigger concept in its own right, referring to a new way for organizations to respond faster to customer demand, build new partnerships or react to market changes.

Vendor ecosystem. At the moment there is no single vendor leading the market for SaaS delivered solutions. Jostling for dominance in this market are traditional applications vendors, infrastructure vendors, pure play SaaS vendors and services providers.

SaaS in the enterprise. SaaS looks set to continue pervading the enterprise, whether through those application areas that suit Internet-based delivery, such as web conferencing and collaboration tools, to those that were previously considered as necessary to be kept behind the firewall: helpdesk, back-up software, word processing, spreadsheets, slideshows, content management and even supply chain management software.

Discover

• What’s the difference between SaaS and traditional on-site implementations?

• Will any of these alternative software models become the primary way that organisations buy software?

• How is today’s hosting model different to the ill-fated ASP model of the 1990s?

• Where does hosting fit in and how does it differ?

• What are the limitations of these software delivery models?

• Who are the leading vendors in this space? And is there a market leader yet?

For more information, kindly visit :
http://www.aarkstore.com/reports/The-Future-of-Software-Delivery-The-opportunities-and-challenges-of-emerging-software-delivery-models-13963.html

Negotiating the Emerging Biosimilars Landscape: Key Developments in the Regulatory Environment

As regulatory obstacles to biosimilars development have become increasingly resolved, a growing number of opportunities have been created for generics companies in the biopharmaceutical market, which according to IMS data was valued at $85.9 billion in 2007. Conservative projections estimate that sales of biopharmaceutical products will exceed $135 billion by 2011. With some of the earliest biopharmaceuticals having already lost patent protection, the originators of biopharmaceutical products are facing intense competition from generics developers. In response, originators are resorting to a range of defensive tactics, including the reformulation of existing products to improve efficacy, the implementation of more efficient delivery systems and the pursuit of high-level intellectual property (IP) battles.

‘Negotiating the Emerging Biosimilars Landscape’ is a new report published by Business Insights that examines the structure of the biopharmaceutical industry and the strategic approaches taken to alleviate the threat posed by the biosimilar market. The key factors affecting market access within the biosimilars market are assessed and the latest issues surrounding bioequivalence are examined. This report also provides a comprehensive review of the current legislative and regulatory positions of key geographic regions in addition to evaluating their anticipated future legislative changes and outcomes.

Key Findings

European Union guidelines have been prepared which authorise the use of specific therapeutic biopharmaceutical medicines as biosimilars. However, despite the range of current European guidelines produced by the EMEA, many European governments have issued laws prohibiting the automatic substitution of original products.

No approval pathway for biosimilars (FOB) exists in the USA, and one is unlikely to exist before 2010. A complex range of Acts and Bills have failed to resolve a number of outstanding legal and regulatory issues.

India’s biopharmaceutical industry is projected to grow to almost $5 billion by the end of 2010, representing annual growth in excess of 30%. However, despite WTO membership and recent advances in compliance with international regulatory/intellectual property laws, there remains no formal regulatory framework for biosimilars in India or China.

Health Canada has not yet publicly announced a legal or regulatory framework for biosimilar approval, and no legal framework for biosimilars currently exists in Japan. New regulatory frameworks and biosimilar guidelines are currently under development in both countries.

Use this report to…

• Identify and respond to the challenges and threats posed by the emergence of the biosimilars industry with this report’s examination of key trends and strategic approaches used by the biopharmaceutical industry to protect market share and intellectual property.
• Examine details of expired patents or impending patent expiries for first-gen biopharmaceuticals derived from recombinant DNA such as interferons, human insulin and insulin analogs, monoclonal antibodies (Mab) growth hormone and epoietins.
• Evaluate the legislative and regulatory requirements for biosimilars across key geographic regions including Europe, the US, Japan, Australia, Canada as well as the strategically important emerging markets of China and India.
• Assess the factors affecting biosimilar market access with this report’s analysis of the drivers and restraints to biosimilar approval, use and uptake, in addition to an investigation of the problems associated with determining bioequivalence.

Explore issues including…

Impending patent expiries. The critical challenge facing the biopharmaceutical industry is the expiry or pending expiry of patents for first generation biopharmaceuticals derived from recombinant DNA such as interferons, growth hormone and epoietins.

Defensive strategies. As part of efforts to protect the market share of products with impending patent expiries, originator biopharmaceutical companies have begun to protect intellectual property and engage in strategic alliances, joint ventures and mergers between themselves and major pharma companies.

Geographical disparities in biosimilar legislation. Different geographic regions have varying legislative approaches to the regulation and/or approval of biosimilars. Such discrepancies often lead to misunderstandings and can result in complexity and complication during the approval process.

Discover…

• Which biopharmaceutical companies are at risk from product patent expires?
• What is the status of the analytical techniques used for determining bioequivalence?
• What tactics prove most effective for originator biopharmaceutical companies who wish to protect their market position?
• What effect the market entry of second generation biopharmaceuticals by originator companies have on the biosimilars market?
• What are the growth drivers and restraints of the biosimilars market?
• How are global healthcare costs influenced by biosimilar market entry prospects?
• What is the current legislative and regulatory status of biosimilars in Europe and the US?
• How will China and India influence the biopharmaceutical and biosimilars market in the future?

For more information, kindly visit :
http://www.aarkstore.com/reports/Negotiating-the-Emerging-Biosimilars-Landscape-Key-Developments-in-the-Regulatory-Environment-13944.html

The Top 10 Food and Drinks Ingredient Companies: Emerging opportunities, growth strategies and innovation in the leading players – Aarkstore Enterprise

The global food and drinks market was worth $3,498bn in 2007, up 3.1% over 2006. The global food and drinks market is anticipated to grow at a CAGR of 3.2% during 2007-10 to reach $3,843bn in 2010. Increasing demand for healthy products coupled with rising disposable incomes in emerging economies is fueling demand for food and drink products. However, the rising price of raw materials such as animal feed, energy, and other commodities such as aluminium used in packaging, will increase the operating costs of players.

‘The Top 10 Food and Drinks Companies: Emerging opportunities, growth strategies and innovation in the leading players’ is a new report published by Business Insights that analyzes the innovation and growth strategies of the top 10 players in the food and drinks industry. This report identifies the product areas that the top 10 players are seeking to develop. It also examines the comparative strengths, weaknesses, opportunities and threats facing the world’s leading food and drinks companies.

Key Findings…

Rising consumption of food and drinks in emerging countries, elevated fuel prices, and climate change have contributed to the rise in raw material prices, which will adversely impact the operating margins of food and drinks companies.

The food and drinks industry is highly fragmented – the top 10 companies account for 12.9% of the global market share, based on 2007 sales.

Consolidation in the food and drinks industry will change its competitive landscape as JBS expected to appear in the top 10 players list in the industry.

Nestlé is the global leader with 2.6% market share in 2007, followed by Cargill with 2.5%.

Use this report to…

• Gain insight into the world’s leading food and drinks companies with this report’s ranking of the top 10 companies, detailing their financial performance and future prospects.
• Identify and target future growth areas from this report’s analysis of acquisitions and divestments made by leading food and drinks companies and their strategies for growth.
• Understand the key trends in the food and drinks market and the impact that they are expected to have on the top 10 players.
• Enhance your product development strategies by examing the leading food and drinks companies’ innovation and NPD strategies and recent product launches.
• Create more effective competitive strategies based on this report’s SWOT analyses of the top food and drinks companies.

Key issues…

Food safety. Rising concerns over the safety of Chinese food products has led its government to draft a five year food safety plan to place new controls on food and drug imports and exports.

Price fixing. Rising raw-material prices and emergence of huge agricultural conglomerates have pushed players to collude and form cartels to co-ordinate pricing for mutual benefit at the expense of buyers.

Growth in Asia Pacific markets. A rising middle class population and an improving macroeconomic environment in the Asian economies of India and China has increased consumption of food and drinks in these countries.

Rising raw material costs. Prices of raw materials such as barley, sorghum, oats, maize (coarse grains) and wheat have been rising sharply due to extensive use of these products in biofuel production, elevated fuel prices and climate change. This has had a negative impact on the operating margins of the food and drinks companies.

Your questions answered…

• What are the drivers and resistors of growth of food and drinks industry?
• Which regions offer the leading food and drinks companies the greatest growth opportunities?
• What are the key trends in the global food and drinks industry?
• Who are the top 20 players in the food and drinks industry?
• What is the market share of each of the global food and drinks leaders by company?
• How do the leading food and drinks companies compare in terms of financial performance and coverage by country and category?
• What are the key strategies of the leading food and drinks companies and how do these strategies drive revenue and market share?

 For more information, kindly visit :
http://www.aarkstore.com/reports/The-Top-10-Food-and-Drinks-Ingredient-Companies-Emerging-opportunities-growth-strategies-and-innovation-in-the-leading-players-13945.html

Technology Transfer Strategies: Maximizing The Returns From New Technologies – Aarkstore Enterprise

Technology transfer is a long-established part of early-stage research within the pharmaceutical and biotechnology industries. Although technology transfer offices have traditionally been associated with inefficiency and a lack of commercial judgment, recent trends have shown improvements in staffing, expertise and service levels. However, the tech transfer function has recently suffered from ‘funding gaps’ for promising new technologies. A clear disparity exists between current service offerings and demand levels amongst investors/industry partners, while the lack of an established model for effective technology transfer function and significant regional variations are major obstacles to future progress.

‘Technology Transfer Strategies’ is a new, uniquely themed report provides a comprehensive examination of the major trends in technology transfer activity in the US, Canada and Europe. The report provides a detailed country-level analysis of technology transfer and associated intellectual property technology regulations, in addition to evaluating the key approaches to office structuring and strategies to negotiate the ’funding gap’. A series of in-depth interviews also document the experiences and insights of 11 tech transfer experts, and their recommendations for successful technology transfer strategies are revealed.

Key Findings

The number of new technology transfer licensing agreements ‘earned’ for every $1 billion of research expenditure has fallen from 115 to 109 between 2004 and 2006. However, the rate of return for licensing revenues per $1 million research expenditure has increased over the same period, from $34,806 to $40,837.

The efficiency of technology transfer outcomes varies across major regions. The UK produces the highest rate of invention disclosures, licensing agreements and new start-ups. The US produces the greatest rate of new patent grants, while Canada generates the most new patent applications. US institutions also generate the greatest technology licensing returns from research investments.

A common industry complaint about interactions with technology transfer offices is ‘a lack of understanding about customer needs’. Tech transfer executives are often viewed to better understand the merits of scientific over commercial solutions.

Generating a successful initial public offering (IPO) has become more difficult, putting increased pressure on associated royalty rates and spin-out terms. As venture capitalists become more conservative, moving new technologies from federal funding to proof-of-concept is increasingly challenging.

Use this report to…

• Identify the latest trends in technology transfer and compare the relative efficiencies of different regions with this report’s detailed survey data of technology transfer performances in the US, Canada and Europe.
• Compare the progress of leading peer-group universities and institutions by using this report’s league table assessment of leading technology transfer offices including healthcare patent data and overall technology transfer outcomes.
• Benchmark the best practices of leading technology transfer offices in the US and Europe by using in-depth case studies that examine successful strategies and approaches to office structuring.
• Assess the strategic recommendations and future predictions of technology transfer specialists based on insights from interviews with eleven experts from universities, hospitals, research institutions and independent companies, in addition to contributions from venture capital and pharmaceutical industry executives.

Explore issues including.

The funding gap. The difficulty of translating basic research to commercial licensing opportunities has never been greater, particularly as VCs and industry clients become more risk averse.

Defensive strategies. Moving technologies beyond basic research to proof of concept is expensive but has become a necessary step in the current technology transfer environment

Cultural differences. Technology transfer offices are positioned between the academic and business worlds, and must balance the non-profit and for-profit worlds accordingly.

Integration vs independence. Recent trends, particularly in the UK, have seen a move towards establishing independent technology transfer offices in order to facilitate greater levels of professionalism and commercialism.

Discover…

• How do intellectual property rights differ by geography?
• How does the availability of potential collaborators and licensing partners differ by geography?
• How does the availability of human resources vary by geography?
• What are the alternative models for delivering technology transfer?
• What impact does each model of tech transfer delivery have upon commercial returns, operational effectiveness and culture/process?
• What are the key lessons from current technology transfer best-practices?
• How does the funding gap influence returns from technology transfer?
• What strategies can effectively combat the funding gap?

  For more information, kindly visit :
  http://www.aarkstore.com/reports/Technology-Transfer-Strategies-Maximizing-The-Returns-From-New-Technologies-13946.html

Switching to Natural Food and Drinks Ingredients: Emerging Opportunities in Wellbeing, Functional and Specialty Ingredients – Aarkstore Enterprise

Switching to Natural Food and Drinks Ingredients Emerging opportunities in wellbeing, functional and specialty ingredients
 
 Natural products are gaining popularity as consumers increasingly avoid artificial additives. Driven by reports about adverse effects of synthetic ingredients such as increasing incidence of allergies or behavioral changes in children, consumers are switching to natural ingredients. At the same time awareness about the functional benefits of natural ingredients is increasing. As a consequence, ingredient manufacturers are increasingly looking to provide natural ingredients as well as natural flavors and colorings to the industry, while end product manufacturers seek to replace artificial additives with natural alternatives. Switching to Natural Ingredients is a new ingredients that provides insight into the top flavors and ingredients and trends for the near future. This report also presents and evaluates key players in the area of natural ingredients and their innovation strategies. Discover the areas of opportunity in natural ingredients and understand how these opportunities fit into larger ingredients industry trends with this new report…
 
 Health benefits. Many natural ingredients have inherent health benefits that are still not fully elucidated by science. This provides opportunities for building consumer confidence, and for proprietary health claims.
 
 Exotic flavors. Established fruity sweet flavors are declining while exotic flavors and specialty flavors such as Goji are gaining share in use in natural food and drinks. This reflects another current consumer trend for new and exotic flavors.
 
 Allergen and intolerance markets are growing with a CAGR of 10.5% from 2001 through 2006, which reflects increasing concern about allergy among consumers. This is among the main drivers towards natural food and drinks.
 
 Healthy Indulgence. A number of natural ingredients such as exotic spices constitute an ideal fusion between indulgence and health and appeal to consumers on two levels.
 
 This new report will enable you to
 
 Quantify and target future growth areas in natural ingredients based on this report’s global market and statistical data from 2001-11. Including analysis of sales of natural ingredients by category, industry, region, flavor and ingredient in Europe and the US.
 
 Improve the targeting and effectiveness of your NPD strategy with this report’s analysis of top and fast growth flavors in the natural ingredients market, using data of over 54,000 products launched globally between 2006 and 2009.
 
 Implement the best-practice strategies of leading innovators in the natural ingredients market using this report’s analysis of key players including Wild, Chr Hansen, Frutarom, Treatt, Vitiva, Coca-Cola, Cadbury Schweppes, Danone and Kellogg.
 
 Identify the drivers and key issues effecting the natural ingredients market. Including changing regulation in the EU and US and gain insight into how this will impact product formulation and marketing in 2009 and beyond.

For more information, kindly visit :
http://www.aarkstore.com/reports/Switching-to-Natural-Food-and-Drinks-Ingredients-Emerging-Opportunities-in-Wellbeing-Functional-and-Specialty-Ingredients-13940.html